Is Bikeren Prenol Tablets (Bituvi) a blocking drug and analysis of its mechanism of action

Biktarvy tablets (Biktarvy) is a compound drug used for the treatment of AIDS (HIV). It consists of Bictegravir (Bicte gravir), emtricitabine (Emtricitabine) and tenofovir arafenib (Tenofovir Composed of alafenamide, TAF). Strictly speaking, Bitovil is not a "blocking drug" in the traditional sense, but a combination of antiretroviral drugs that inhibits HIV viral replication through multiple mechanisms, thereby controlling viral load. It combines the action characteristics of integrase inhibitors and nucleoside reverse transcriptase inhibitors, and can produce sustained inhibitory effects on viruses.

Bictegravir in Bituvi is an integrase inhibitor (INSTI). Its main mechanism of action is to block the process by which HIV viral integrase integrates viral DNA into the host cell genome. Through this action, the virus is unable to complete its replication cycle within the host cell, preventing the production of new viruses. Bictegravir has high affinity and long-lasting effects, and can effectively inhibit integrase activity while reducing the risk of drug resistance.

Emtricitabine and tenofovir arafenib are both nucleoside or nucleotide reverse transcriptase inhibitors (NRTI). They work by incorporating into the ends of viral DNA chains, causing chain termination, thereby blocking the process by which HIV reverse transcriptase transcribes viral RNA into DNA . This mechanism is complementary to integrase inhibitors, and their combined effect can significantly reduce viral replication efficiency. The combined use of the three drugs can form an efficient multiple inhibitory barrier to prevent rapid viral replication and the generation of drug-resistant mutations.

In general, Bitovil is not a simple blocking drug, but a multi-mechanism anti-HIV HIV drug combination. It inhibits virus replication, integration and spread from the source through the dual effects of integrase inhibition and reverse transcriptase inhibition. In clinical application, this combined mechanism can quickly reduce viral load, improve immune function, simplify medication regimens, and improve patient compliance. For HIV patients, the mechanism of action of Bituvi ensures long-term effective suppression of the virus and reduces the risk of drug resistance. It is an important choice for the current first-line treatment against HIV with both safety and efficacy.

Reference materials:https://www.nlm.nih.gov/